Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 504-518

  Fredolini, Claudia ^a,b,d   Meani, Francesco ^c,d   Luchini, Alessandra ^d   Zhou, Weidong ^d   Russo, Paul ^d   Ross, Mark ^d   Patanarut, Alexis ^d   Tamburro, Davide ^d,e   Gambara, Guido ^d   Ornstein, David ^f   Odicino, Franco ^c   Ragnoli, Monica ^c   Ravaggi, Antonella ^c   Novelli, Francesco ^b   Collura, Devis ^a   D'Urso, Leonardo ^a   Muto, Giovanni ^a   Belluco, Claudio ^g   Pecorelli, Sergio ^c   Liotta, Lance ^d   Petricoin III, Emanuel F ^d   more..

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d GEORGE MASON UNIVERSITY   (United States)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Biomarker; Cancer; Mass spectrometry; Nanoparticle; Peptidome

Indexed keywords

ALPHA ACTININ 1; ALPHA TUBULIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C; ARYLDIALKYLPHOSPHATASE 1; CADHERIN; COFILIN 1; CYTOKERATIN 9; FIBRINOGEN; FILAMIN A; HAPTOGLOBIN; HEPARANASE; NANOPARTICLE; PEPTIDOME; PLECKSTRIN; SERINE; THROMBOSPONDIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; HYDROGEL; MALE; MOLECULAR WEIGHT; OVARY CANCER; PILOT STUDY; PROSTATE CANCER; PROTEIN ANALYSIS;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, GEL; EARLY DIAGNOSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDE MAPPING; PROSTATIC NEOPLASMS; PROTEOME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 78649686020     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9211-3     Document Type: Article

References (58)

1. ED Crawford 2009 Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 Suppl 5 4 10 10.1016/j.urology.2009.03.001
2. MJ Barry 2001 Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer N Engl J Med 344 1373 1377 10.1056/NEJM200105033441806 11333995 1:STN:280:DC%2BD3M3kvFejtQ%3D%3D (Pubitemid 32378393)
3. FH Schröder J Hugosson MJ Roobol ERSPC Investigators, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 1320 1328 10.1056/NEJMoa0810084 19297566
4. CG Roehrborn 2008 The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia Int J Impot Res 20 Suppl 3 S19 S26 10.1038/ijir.2008.53 19002120
5. IA Thompson DK Pauler PJ Goodman, et al. 2004 Prevalence of prostate cancer among men with a prostate-specific antigen level of ≤4.0 ng per milliliter N Engl J Med 350 2239 2246 10.1056/NEJMoa031918 15163773 1:CAS:528:DC%2BD2cXksVehsr8%3D (Pubitemid 38669206)
6. Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER Cancer Stat Fact Sheets. 2009, Bethesda, MD. National Cancer Institute. http://seer.cancer.gov/ statfacts/html/ovary.html, accessed December 2, 2009.
7. AN Rosenthal U Menon IJ Jacobs 2006 Screening for ovarian cancer Clinical Obstetrics and Gynecology 49 433 447 10.1097/00003081-200609000-00004 16885651 (Pubitemid 44181417)
8. MJ Duffy JM Bonfrer J Kulpa, et al. 2005 CA125 in ovarian cancer. European Group on Tumor Markers guidelines for clinical use Int J Gynecol Cancer 15 679 691 10.1111/j.1525-1438.2005.00130.x 16174214 1:STN:280: DC%2BD2Mrgt1Klsw%3D%3D (Pubitemid 41783071)
9. RC Bast Jr 2003 Status of tumor markers in ovarian cancer screening J Clin Oncol 21 Suppl 10 200s 205s 10.1200/JCO.2003.01.068 12743135
10. NS Azad N Rasool CM Annunziata L Minasian G Whiteley EC Kohn 2006 Proteomics in clinical trials and practice: present uses and future promise Mol Cell Proteomics 5 1819 1829 10.1074/mcp.R600008-MCP200 16737951 1:CAS:528:DC%2BD28XhtFGqsbbJ (Pubitemid 44688191)
11. SS Buys E Partridge MH Greene, et al. 2005 Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial Am J Obstet Gynecol 193 1630 1639 10.1016/j.ajog.2005.05.005 16260202 (Pubitemid 41540458)
12. SJ Skates U Menon N MacDonald, et al. 2003 Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women J Clin Oncol 21 Suppl 10 206 210s 10.1200/JCO.2003.02.955
13. U Menon SJ Skates S Lewis, et al. 2005 Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer J Clin Oncol 23 7919 7926 10.1200/JCO.2005.01.6642 16258091 (Pubitemid 46657391)
14. FS Berven K Flikka M Berle, et al. 2006 Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis Curr Pharm Biotechnol 7 147 158 10.2174/138920106777549713 16789900 1:CAS:528: DC%2BD28XnslOku78%3D (Pubitemid 43881079)
15. A Farina JM Dumonceau P Lescuyer 2009 Proteomic analysis of human bile and potential applications for cancer diagnosis Expert Rev Proteomics 6 285 301 10.1586/epr.09.12 19489700 1:CAS:528:DC%2BD1MXms12nu7o%3D
16. T Jamaspishvili M Kral I Khomeriki, et al. 2010 Urine markers in monitoring for prostate cancer Prostate Cancer Prostatic Dis 13 12 19 10.1038/pcan.2009.31 19652665 1:CAS:528:DC%2BC3cXhslOhtL4%3D
17. RR Drake KY White TW Fuller E Igwe MA Clements JO Nyalwidhe, et al. 2009 Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease J Proteomics 72 907 917 10.1016/j.jprot.2009.01.007 19457353 1:CAS:528:DC%2BD1MXptlSrsr0%3D
18. HJ Issaq Z Xiao TD Veenstra 2007 Serum and plasma proteomics Chem Rev 107 3601 3620 10.1021/cr068287r 10.1021/cr068287r 17636887 1:CAS:528: DC%2BD2sXnslGqsLw%3D (Pubitemid 47333550)
19. M Zhou DA Lucas KC Chan HJ Issaq EF Petricoin 3rd LA Liotta, et al. 2004 An investigation into the human serum "interactome" Electrophoresis 25 1289 1298 10.1002/elps.200405866 15174051 1:CAS:528:DC%2BD2cXks12ht7s%3D (Pubitemid 38801647)
20. YY Wang P Cheng DW Chan 2003 A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis Proteomics 3 243 248 10.1002/pmic.200390036 12627376 1:CAS:528:DC%2BD3sXisVCgu78%3D (Pubitemid 36343679)
21. RL Gundry JE Van Eyk 2007 Unraveling the complexity of circulating forms of brain natriuretic peptide Clin Chem 53 1181 1182 10.1373/clinchem.2007.086611 17582147 1:CAS:528:DC%2BD2sXntlCqsLo%3D (Pubitemid 47020969)
22. MS Lowenthal AI Mehta K Frogale RW Bandle RP Araujo BL Hood, et al. 2005 Analysis of albumin-associated peptides and proteins from ovarian cancer patients Clin Chem 51 1933 1945 10.1373/clinchem.2005.052944 16099937 1:CAS:528:DC%2BD2MXhtVGmtbjE (Pubitemid 41368193)
23. RS Tirumalai KC Chan DA Prieto HJ Issaq TP Conrads TD Veenstra 2003 Characterization of the low molecular weight human serum proteome Mol Cell Proteomics 2 1096 1103 10.1074/mcp.M300031-MCP200 12917320 1:CAS:528: DC%2BD3sXovFWmt7s%3D
24. LA Liotta M Ferrari E Petricoin 2003 Clinical proteomics: written in blood Nature 425 905 10.1038/425905a 14586448 1:CAS:528:DC%2BD3sXosVOhsb0%3D (Pubitemid 37376908)
25. AJ Rai CA Gelfand BC Haywood DJ Warunek J Yi MD Schuchard, et al. 2005 HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples Proteomics 5 3262 3277 10.1002/pmic.200401245 16052621 1:CAS:528:DC%2BD2MXps12it7k%3D (Pubitemid 41192034)
26. A Luchini DH Geho B Bishop, et al. 2008 Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation Nano Lett 8 350 361 10.1021/nl072174l 18076201 1:CAS:528:DC%2BD2sXhsVWgu7zN (Pubitemid 351177827)
27. C Fredolini F Meani K Alex Reeder, et al. 2008 Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles Nano Res 1 502 518 10.1007/s12274-008-8054-z 20467576 1:CAS:528:DC%2BD1MXhtFSjtr3K
28. C Longo A Patanarut T George B Bishop W Zhou C Fredolini, et al. 2009 Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers PLoS One 4 3 e4763 10.1371/journal.pone.0004763 19274087 1:CAS:528:DC%2BD1MXjt1Ohtrg%3D (Epub 2009 Mar 10.B)
29. FE Ahmed 2009 Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry J Sep Sci 32 771 779 10.1002/jssc.200900014 19219839 1:CAS:528:DC%2BD1MXms1KjsL8%3D
30. LN Mueller MY Brusniak DR Mani R Aebersold 2008 An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data J Proteome Res 7 51 61 10.1021/pr700758r 18173218 1:CAS:528: DC%2BD1cXitFakuw%3D%3D (Pubitemid 351171115)
31. CH Streuli 2009 Integrins and cell-fate determination J Cell Sci 122 171 177 10.1242/jcs.018945 19118209 1:CAS:528:DC%2BD1MXit1GqtLo%3D
32. BP Eliceiri 2001 Integrin and growth factor receptor crosstalk Circ Res 89 1104 1110 10.1161/hh2401.101084 11739274 1:CAS:528:DC%2BD3MXptFKitL4%3D
33. EH Danen KM Yamada 2001 Fibronectin, integrins, and growth control J Cell Physiol 189 1 13 10.1002/jcp.1137 11573199 1:CAS:528:DC%2BD3MXms12lsLs%3D (Pubitemid 32830418)
34. A Howe AE Aplin SK Alahari RL Juliano 1998 Integrin signaling and cell growth control Curr Opin Cell Biol 10 220 231 10.1016/S0955-0674(98)80144-0 9561846 1:CAS:528:DyaK1cXisFyntLs%3D (Pubitemid 28174764)
35. A Hall 2009 The cytoskeleton and cancer Cancer Metastasis Rev 28 5 14 10.1007/s10555-008-9166-3 19153674
36. JS Desgrosellier DA Cheresh 2010 Integrins in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 10 9 22 10.1038/nrc2748 20029421 1:CAS:528:DC%2BD1MXhsF2hsLzI
37. HL Goel J Li S Kogan LR Languino 2008 Integrins in prostate cancer progression Endocr Relat Cancer. 15 657 664 10.1677/ERC-08-0019 18524948 1:CAS:528:DC%2BD1cXhtlWit7bE (Epub 4 Jun 2008)
38. D Monniaux C Huet-Calderwood F Le Bellego S Fabre P Monget DA Calderwood 2006 Integrins in the ovary Semin Reprod Med 24 251 261 10.1055/s-2006-948554 16944422 1:CAS:528:DC%2BD28XhtV2jsr3E (Pubitemid 44387529)
39. GJ Mizejewski 1999 Role of integrins in cancer: survey of expression patterns Proc Soc Exp Biol Med 222 124 138 10.1046/j.1525-1373.1999.d01-122.x 10564536 1:CAS:528:DyaK1MXntFCgtr4%3D
40. S Weivoda JD Andersen A Skogen PM Schlievert D Fontana T Schacker, et al. 2008 ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand J Immunol Methods. 336 22 29 10.1016/j.jim.2008.03.004 18436231 1:CAS:528:DC%2BD1cXmtlSltbw%3D (Epub 4 Apr 2008)
41. R Shirai F Hirano N Ohkura K Ikeda S Inoue 2009 Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response Biochem Biophys Res Commun 382 776 779 10.1016/j.bbrc.2009.03.104 19324010 1:CAS:528:DC%2BD1MXkslymtL8%3D (Epub 24 Mar 2009)
42. JD Andersen KL Boylan FS Xue LB Anderson BA Witthuhn TW Markowski, et al. 2010 Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis Electrophoresis 31 599 610 10.1002/elps.200900441 20162585 1:CAS:528: DC%2BC3cXit1amsr8%3D
43. T Kakisaka T Kondo T Okano K Fujii K Honda M Endo, et al. 2007 Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 852 257 267 10.1016/j.jchromb.2007.01.029 1:CAS:528:DC%2BD2sXmtVGms7c%3D (Pubitemid 46830120)
44. T Kawakami Y Hoshida F Kanai Y Tanaka K Tateishi T Ikenoue, et al. 2005 Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment Proteomics 5 4287 4295 10.1002/pmic.200401287 16254924 1:CAS:528:DC%2BD2MXht1GrtbrL (Pubitemid 41626096)
45. T Okano T Kondo T Kakisaka K Fujii M Yamada H Kato, et al. 2006 Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis Proteomics 6 3938 3948 10.1002/pmic.200500883 16767791 1:CAS:528:DC%2BD28XntlCjtro%3D (Pubitemid 44065171)
46. Y Chen BK Lim OH Hashim 2009 Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma J Hematol Oncol 2 37 10.1186/1756-8722-2-37 19709441 1:CAS:528:DC%2BD1MXhtVynsrjI
47. Y Chen BK Lim SC Peh PS Abdul-Rahman 2008 Hashim OH profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma Proteome Sci 6 20 10.1186/1477-5956-6-20 18637207 1:CAS:528:DC%2BD1cXps1Wlsrw%3D
48. S Weivoda JD Andersen A Skogen PM Schlievert D Fontana, et al. 2008 ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand J Immunol Methods 336 22 29 10.1016/j.jim.2008.03.004 18436231 1:CAS:528:DC%2BD1cXmtlSltbw%3D Epub 2008 Apr 4
49. DR Schwartz SL Kardia KA Shedden R Kuick G Michailidis JM Taylor, et al. 2002 Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas Cancer Res 62 4722 4729 12183431 1:CAS:528:DC%2BD38XmsVShsb8%3D
50. KA Paschos D Canovas NC Bird 2009 The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis Cell Signal. 21 665 674 10.1016/j.cellsig.2009.01.006 19167485 1:CAS:528:DC%2BD1MXisFWjsL4%3D (Epub 7 Jan 2009)
51. L Heyman J Leroy-Dudal J Fernandes D Seyer S Dutoit F Carreiras 2010 Mesothelial vitronectin stimulates migration of ovarian cancer cells Cell Biol Int 34 493 502 10.1042/CBI20090331 20121701 1:CAS:528:DC%2BC3cXkvVOiu78%3D
52. M Goodwin AS Yap 2004 Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton J Mol Histol 35 839 844 10.1007/s10735-004-1833-2 15609097 1:CAS:528:DC%2BD2MXhsVyrs7o%3D (Pubitemid 41404630)
53. B Felding-Habermann DA Cheresh 1993 Vitronectin and its receptors Curr Opin Cell Biol 5 864 868 10.1016/0955-0674(93)90036-P 7694604 1:CAS:528:DyaK3sXmsVKgt7w%3D
54. O De Wever L Derycke A Hendrix G De Meerleer F Godeau H Depypere, et al. 2007 Soluble cadherins as cancer biomarkers Clin Exp Metastasis 24 685 697 10.1007/s10585-007-9104-8 17952616 1:CAS:528:DC%2BD1cXhvFGgtrk%3D (Pubitemid 350159736)
55. EM Hurt K Chan MA Serrat SB Thomas TD Veenstra WL Farrar 2010 Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation Stem Cells 28 390 398 19998373 1:CAS:528:DC%2BC3cXlvVGlt7o%3D
56. CR Cooper CH Chay KJ Pienta 2002 The role of alpha(v)beta(3) in prostate cancer progression Cooper Neoplasia. 4 191 194 10.1038/sj.neo.7900224 1:CAS:528:DC%2BD38XksFGnu74%3D
57. R Kuefer MD Hofer JE Gschwend, et al. 2003 The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer Clin Cancer Res 9 6447 6452 14695147 1:CAS:528:DC%2BD3sXhtVSqurrE
58. R Kuefer MD Hofer CS Zorn O Engel BG Volkmer MA Juarez-Brito, et al. 2005 Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer Br J Cancer 92 2018 2023 10.1038/sj.bjc.6602599 15870707 1:CAS:528:DC%2BD2MXks1GntLY%3D (Pubitemid 40897424)